

IntelGenx Technologies Corp.  
Form 8-K  
February 07, 2011

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**Current Report**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**February 7, 2011**  
*Date of Report (Date of Earliest Event Reported)*

**IntelGenx Technologies Corp.**  
*(Exact Name of Registrant as Specified in its Charter)*

<b>Delaware</b> <i>(State or other jurisdiction of incorporation)</i>	<b>000-31187</b> <i>(Commission File Number)</i>	<b>870299034</b> <i>(IRS Employer Identification No.)</i>
6425 Abrams, Ville St- Laurent, Quebec, Canada H4S 1X9 <i>(Address of principal executive offices) (Zip Code)</i>		

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 7.01 Regulation FD Disclosure - News Release**

**IntelGenx Achieves Positive Bioequivalence Results for a Leading Branded Anti-Psychotic Using VersaFilm Oral Thin Film Technology**

Exhibit Description

99.1 Press Release

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGENX TECHNOLOGIES CORP.**

Dated: February 7, 2011

By: /s/ Horst Zerbe  
Horst G. Zerbe  
President and Chief  
Executive Officer

---